List of Excipients in Branded Drug CEFAZOLIN SODIUM

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
B Braun Medical Inc	CEFAZOLIN SODIUM	cefazolin sodium	0264-3103	DEXTROSE MONOHYDRATE
B Braun Medical Inc	CEFAZOLIN SODIUM	cefazolin sodium	0264-3103	WATER

Cefazolin Sodium Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Cefazolin sodium is a mature, largely commoditized injectable cephalosporin. Its commercial opportunity is not based on new-molecule exclusivity. It is based on excipient selection, container-closure performance, supply reliability, ready-to-administer formats, antimicrobial-stewardship positioning, and reduction of pharmacy preparation labor.

The strongest product concepts are premixed intravenous bags, longer-stability presentations, low-overfill formats, pediatric dose flexibility, and packaging compatible with automated hospital systems. A conventional sterile powder containing cefazolin sodium and sodium carbonate remains the lowest-cost regulatory pathway, while premixed and ready-to-use products create higher differentiation but require substantially more stability, compatibility, and manufacturing work.

What is cefazolin sodium and how is it supplied?

Cefazolin sodium is a first-generation cephalosporin antibiotic administered primarily by intravenous or intramuscular injection. It is used for perioperative prophylaxis and treatment of susceptible bacterial infections. FDA-approved products include sterile powders for reconstitution and premixed intravenous presentations in diluents such as dextrose or sodium chloride. Product-specific labels govern concentration, reconstitution volume, storage, stability, and administration conditions. (U.S. Food and Drug Administration [FDA], n.d.-a; DailyMed, n.d.-a)

Main dosage forms and presentations

Presentation	Typical excipient profile	Primary commercial advantage	Main technical risk
Sterile powder vial	Cefazolin sodium, often with sodium carbonate or another alkalinizing excipient	Lowest manufacturing and shipping cost	Pharmacy reconstitution burden
Pharmacy bulk package	Cefazolin sodium with alkalinizing excipient	High-volume hospital use	Aseptic handling and in-use dating
Premixed IV bag	Cefazolin sodium in dextrose or sodium chloride	Reduced preparation time and dosing errors	Solution stability and container compatibility
Ready-to-administer syringe	Cefazolin sodium in a compatible aqueous vehicle	Emergency, operating-room, and outpatient convenience	Higher device and stability requirements
Elastomeric infusion device	Cefazolin sodium in a validated diluent	Home infusion and ambulatory care	Drug-device interaction and extended-use stability
Dual-chamber system	Dry cefazolin sodium separated from diluent until activation	Improved shelf life and simplified administration	More complex container and manufacturing process

The most common powder products minimize excipient exposure. Premixed products introduce a much larger formulation design space because the active ingredient remains in solution for the labeled shelf life.

What excipients are used in cefazolin sodium products?

Cefazolin sodium formulations generally use a limited excipient set. Sodium carbonate is commonly used in sterile powder products to support the alkaline pH needed for cefazolin stability. Premixed products may use dextrose injection, sodium chloride injection, or another approved parenteral diluent. Excipients are product-specific and must be confirmed against the applicable FDA labeling. (DailyMed, n.d.-a; DailyMed, n.d.-b)

Sodium carbonate and alkalinity

Sodium carbonate can perform several functions in a cefazolin sodium powder:

• Maintains an alkaline microenvironment.
• Supports chemical stability during storage.
• Improves the reconstitution profile.
• Helps control the pH of the reconstituted solution.
• Provides a familiar excipient platform with extensive parenteral precedent.

The principal commercial limitation is sodium load. Cefazolin sodium already contributes sodium because the drug is supplied as a sodium salt. Added sodium carbonate increases the total sodium burden, which can matter for neonatal, renal, cardiac, and intensive-care populations.

A low-sodium product would require careful evaluation because reducing or removing sodium carbonate may narrow the stability margin. The opportunity is technically attractive, but it should be treated as a formulation-development program rather than a simple excipient substitution.

Dextrose and sodium chloride

Dextrose and sodium chloride are established intravenous vehicles for cefazolin. They allow the product to be supplied as a premixed solution and can align with existing hospital administration practices.

The choice affects:

• Osmolality.
• Sodium exposure.
• Compatibility with peripheral or central administration.
• Container permeability.
• Crystallization risk.
• Chemical degradation rate.
• Use in diabetic, sodium-sensitive, pediatric, and renal patients.
• Integration with hospital stocking systems.

Dextrose-based products may be less attractive for certain diabetic or critically ill patients. Sodium chloride-based products may increase the sodium burden. A portfolio with both vehicles can expand institutional formulary access but increases manufacturing, stability, and inventory complexity.

pH modifiers, buffers, and chelators

Additional buffering systems may improve solution stability but can also create regulatory and compatibility concerns. A buffer must be compatible with cefazolin degradation pathways, container materials, sterilization conditions, and intravenous administration.

Potential development candidates include:

• Carbonate-based systems.
• Phosphate systems, subject to calcium and compatibility concerns.
• Citrate systems, subject to tolerability and metal-ion interactions.
• Low-level chelation strategies, where justified by impurity-control data.
• Antioxidant systems, only if oxidative degradation is demonstrated and the excipient is appropriate for parenteral use.

The commercial case for adding a new excipient is weak unless it produces a measurable benefit, such as longer room-temperature stability, reduced degradation products, reduced sodium load, or compatibility with a new delivery device.

What formulation patents protect cefazolin sodium?

Cefazolin sodium has no meaningful new-molecule patent barrier in the current generic market. Its core composition and antibacterial use have been commercially established for decades. Current competitive protection is more likely to arise from product-specific formulation, container, manufacturing, or delivery-system patents than from cefazolin itself.

Patent opportunities by product type

Product concept	Potential IP subject matter	Likely strength
Conventional powder vial	Specific excipient ratio, impurity profile, moisture control, manufacturing process	Low to moderate
Low-sodium powder	Defined stabilizer system, sodium specification, stability profile	Moderate if technically unexpected
Premixed solution	Concentration, pH range, diluent, degradation limits, shelf life	Moderate
Ready-to-administer syringe	Formulation plus syringe material and storage conditions	Moderate
Elastomeric device	Drug-device compatibility, extended-use stability, administration protocol	Moderate to strong if data are distinctive
Dual-chamber package	Container design, activation mechanism, formulation separation	Stronger device or combination protection
Pediatric formulation	Concentration, dosing flexibility, preservative-free presentation	Usually limited unless technically distinctive

A formulation patent needs more than a routine selection of sodium chloride, dextrose, or sodium carbonate. The applicant would need evidence of an unexpected stability, impurity, usability, or compatibility benefit. Narrow claims supported by comparative data are more defensible than broad claims covering generic parenteral cefazolin formulations.

When does cefazolin sodium lose exclusivity?

Cefazolin sodium is already an off-patent antibiotic. The key commercial barriers are regulatory approval, manufacturing economics, sterile supply, hospital contracting, and product reliability rather than loss of exclusivity.

Exclusivity and patent status

Protection category	Cefazolin sodium position
New chemical entity exclusivity	Expired
Core compound patents	Expired
Standard generic entry	Established
Biosimilar exclusivity	Not applicable
Paragraph IV risk	Relevant only to any currently listed, unexpired product-specific patent
Orange Book value	Potentially relevant for listed formulation or method-of-use patents, but not for basic cefazolin availability
Current competitive barrier	Sterile manufacturing, supply continuity, formulation differentiation, and contracting

A current Orange Book review should be performed for the specific reference-listed product and any relevant approved injectable presentation. FDA’s Orange Book identifies approved drug products and, where applicable, patent and exclusivity information. (FDA, n.d.-b)

What is the FDA regulatory status of cefazolin sodium?

Cefazolin sodium is an FDA-approved prescription antibacterial administered by injection. Generic applicants generally use the abbreviated new drug application pathway when the reference product, dosage form, strength, route, and pharmaceutical equivalence requirements are satisfied. (FDA, n.d.-c)

For a conventional sterile powder, the regulatory burden is comparatively familiar. A premixed or extended-stability product may require more extensive analytical and stability support, including:

• Assay and degradation-product methods.
• Particulate and subvisible-particle control.
• Sterility and container-closure integrity.
• Extractables and leachables.
• In-use and post-reconstitution stability.
• Dilution and administration compatibility.
• Photostability where relevant.
• Shipping and temperature-excursion data.
• Device performance for syringes, bags, or elastomeric systems.

A new formulation may fit the ANDA pathway if it remains pharmaceutically equivalent to an approved reference product. A materially different dosage form, delivery system, or clinical use could require a different regulatory strategy.

What commercial opportunities exist for cefazolin excipient innovation?

1. Premixed intravenous bags

Premixed cefazolin can reduce pharmacy compounding, preparation time, occupational exposure, and medication-error risk. The product is commercially attractive in operating rooms, emergency departments, inpatient wards, ambulatory surgery centers, and outpatient infusion settings.

The principal development target is shelf life at controlled room temperature without unacceptable degradation, precipitation, color change, particulate formation, or container interaction.

2. Longer-stability products

Hospitals value products that remain usable during ordinary inventory cycles and temperature excursions. A formulation with longer refrigerated or room-temperature stability can reduce product waste and improve stock management.

Stability claims must be supported by real-time and accelerated data. A claim that enables broader storage conditions can be commercially valuable, but it also increases the burden of packaging qualification and labeling support.

3. Low-sodium cefazolin

A low-sodium formulation could target neonates, patients with renal impairment, patients with heart failure, and high-volume perioperative protocols. The opportunity depends on proving that sodium reduction does not compromise cefazolin stability or reconstitution.

The commercial message should focus on total sodium exposure per administered dose, not simply the absence of sodium carbonate. Cefazolin sodium itself contributes sodium.

4. Ready-to-administer syringes

Prefilled syringes can support operating-room and emergency use. The value proposition is rapid administration and lower preparation burden. The main barriers are syringe-material compatibility, plunger performance, extractables and leachables, terminal sterilization strategy, and shelf-life maintenance.

A cefazolin syringe is more likely to command a premium in institutional settings when it is integrated into a broader anesthesia, perioperative, or emergency medication portfolio.

5. Elastomeric devices for outpatient therapy

Cefazolin is used in outpatient and home-infusion settings. An elastomeric presentation can remove repeated pharmacy preparation steps and support ambulatory treatment.

The formulation must remain stable for the full labeled administration period. The development package should address:

• Drug-device adsorption.
• Permeation and water loss.
• Microbial control.
• Delivery-rate consistency.
• Temperature during transport and use.
• Compatibility with extension sets and administration tubing.

6. Pediatric and neonatal presentations

Lower-volume, preservative-free, and flexible-concentration formats may improve dosing practicality. A pediatric product must address small dose volumes, dilution accuracy, dead volume, syringe graduation, and storage after reconstitution.

A lower concentration can reduce administration volume but may increase packaging volume and stability risk. A higher concentration can reduce fluid burden but may create infusion-site or compatibility constraints.

How strong is the cefazolin sodium patent estate?

The basic cefazolin patent estate is weak as a barrier to generic entry because the molecule and conventional injectable use are old. New commercial protection would need to come from a differentiated product.

Practical patent-strength assessment

Claim area	Barrier to competitors	Commercial assessment
Cefazolin sodium composition	Low	Commoditized
Conventional sterile powder	Low	Difficult to defend broadly
Specific impurity limits	Low to moderate	Useful when tied to a reproducible process
Premixed stability profile	Moderate	Stronger if unexpected and difficult to reproduce
Container formulation combination	Moderate	Can support product differentiation
Dual-chamber delivery	Moderate to strong	Often supported by device and formulation claims
Extended-use elastomeric system	Moderate to strong	Valuable if supported by robust compatibility data
Manufacturing process	Moderate	Can protect yield, purity, or stability advantages

Trade-secret protection may be more useful than patent protection for process controls, moisture management, sterilization parameters, impurity reduction, and packaging know-how. A company should use patents for externally visible product attributes and trade secrets for manufacturing variables that competitors cannot readily reverse-engineer.

Which companies are challenging cefazolin sodium products?

Cefazolin sodium is supplied through a broad generic and institutional injectable market. Competitive pressure comes from established generic manufacturers, specialty injectable companies, contract manufacturers, and hospital-focused suppliers. Product-specific Paragraph IV litigation is not the primary market issue for conventional cefazolin.

Competition is concentrated in:

• Unit price.
• Shortage performance.
• Contract reliability.
• Vial and bag availability.
• Presentation breadth.
• Pharmacy automation compatibility.
• National wholesaler coverage.
• 503B outsourcing availability where applicable.
• Ability to maintain supply during sterile-manufacturing disruptions.

FDA drug-shortage data and manufacturer-specific product listings should be monitored because injectable antibiotics can experience supply disruption from manufacturing, quality, or capacity constraints. (FDA, n.d.-d)

What generic launch risks exist for a new cefazolin formulation?

A new entrant faces limited patent risk but meaningful execution risk.

Key risks

1. Chemical instability: Cefazolin can degrade in solution, particularly when exposed to unfavorable pH, temperature, or storage duration.
2. Container interaction: Bags, syringes, elastomeric devices, and tubing can affect potency, adsorption, permeability, and leachables.
3. Reconstitution variability: Powder products may show differences in dissolution time, foaming, particulates, or residual volume.
4. Sodium exposure: The total sodium contribution may limit positioning in vulnerable populations.
5. Hospital conversion costs: Pharmacy and nursing departments may resist switching from familiar vial presentations.
6. Low price ceilings: Commodity cefazolin products may not support high development costs without a differentiated delivery format.
7. Supply-chain concentration: Sterile injectable production depends on validated facilities, specialized components, and reliable fill-finish capacity.
8. Labeling constraints: Commercial claims must remain within the approved product label.

How does cefazolin sodium compare with other injectable cephalosporins?

Attribute	Cefazolin sodium	Ceftriaxone sodium	Cefepime hydrochloride	Cefuroxime sodium
Generation	First	Third	Fourth	Second
Common role	Surgical prophylaxis and susceptible infections	Broad inpatient and outpatient use	Serious gram-negative and hospital infections	Perioperative and respiratory indications
Excipient opportunity	Premix, low sodium, pediatric, home infusion	Premix and outpatient convenience	Stability and reconstitution	Premix and hospital workflow
Patent barrier	Low	Low	Low	Low
Main commercial differentiator	Reliability and administration efficiency	Spectrum and dosing convenience	Hospital-acuity positioning	Formulation and contracting

Cefazolin has a strong position in surgical prophylaxis because of established clinical use, familiarity, and relatively low acquisition cost. Its commercial weakness is that the base product is easy to substitute. A premium product therefore needs to reduce labor, waste, preparation risk, or supply disruption.

What licensing deals and partnership models are available?

Cefazolin is more suitable for manufacturing, licensing, and co-development partnerships than for discovery-stage licensing. Relevant deal structures include:

• Regional commercialization rights for premixed products.
• Contract development and manufacturing agreements.
• Hospital-system supply contracts.
• Co-development of elastomeric or dual-chamber presentations.
• Private-label supply for wholesalers and group purchasing organizations.
• Licensing of packaging or drug-device technology.
• Portfolio bundling with other perioperative injectables.

A partner with an approved sterile injectable facility, hospital distribution access, and validated container systems can materially shorten commercialization timelines. The best licensing target is usually a differentiated presentation with an existing customer base, not a conventional cefazolin powder vial.

Key Takeaways

• Cefazolin sodium is an established generic injectable with no meaningful new-molecule exclusivity.
• The strongest opportunity is formulation and delivery convenience, not basic active-ingredient protection.
• Sodium carbonate is a common powder excipient, but total sodium exposure creates a potential low-sodium development angle.
• Premixed bags, ready-to-administer syringes, elastomeric devices, and dual-chamber systems offer the clearest commercial differentiation.
• Product-specific formulation and device patents may be defensible when supported by unexpected stability or compatibility data.
• Manufacturing reliability, hospital contracting, and supply continuity are more important than Paragraph IV litigation for conventional cefazolin.
• A successful product must demonstrate measurable reductions in pharmacy labor, medication waste, administration complexity, or supply risk.

FAQs

Can cefazolin sodium be formulated without sodium carbonate?

Possibly, but the formulation must demonstrate acceptable chemical stability, impurity control, reconstitution, and shelf life without the alkalinizing excipient. Removing sodium carbonate may reduce sodium exposure but can narrow the stability margin.

Is cefazolin sodium suitable for a prefilled syringe?

Yes, subject to formulation and container-closure development. The sponsor must establish syringe-material compatibility, extractables and leachables, dose accuracy, sterility, particulate control, and shelf life.

Does cefazolin sodium have biosimilar competition?

No. Biosimilar regulation applies to biological products. Cefazolin sodium is a chemically synthesized small-molecule drug, so competition occurs through generic drug pathways.

Can a new cefazolin excipient formulation obtain patent protection?

Yes, if the formulation has a novel and non-obvious combination of excipients, concentration, pH, container, stability profile, or delivery system. Broad claims covering routine injectable excipients are less likely to provide durable protection.

Is cefazolin sodium commercially attractive for home infusion?

It can be attractive where a validated elastomeric or ready-to-use system provides reliable extended-use stability, simple administration, and lower pharmacy preparation requirements. The opportunity depends on device compatibility and reimbursement economics.

References

DailyMed. (n.d.-a). Cefazolin sodium injection, powder, for solution: Product labeling. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

DailyMed. (n.d.-b). Cefazolin sodium in dextrose injection: Product labeling. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

U.S. Food and Drug Administration. (n.d.-a). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

U.S. Food and Drug Administration. (n.d.-c). Abbreviated new drug application (ANDA). https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda

U.S. Food and Drug Administration. (n.d.-d). Drug shortages. https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages